Literature DB >> 19565192

Classification of FABP isoforms and tissues based on quantitative evaluation of transcript levels of these isoforms in various rat tissues.

Takenori Yamamoto1, Atsushi Yamamoto, Masahiro Watanabe, Taisuke Matsuo, Naoshi Yamazaki, Masatoshi Kataoka, Hiroshi Terada, Yasuo Shinohara.   

Abstract

In mammals, 10 isoforms of fatty acid-binding protein (FABP) are expressed in various tissues. To understand the role of multiple FABP isoforms, we have quantitatively examined the transcript levels of individual FABP isoforms in each of various tissues by Northern blotting using synthesized RNAs corresponding to the mRNA of each isoform as external standards. As a result, absolute transcript levels of individual FABP isoforms expressed in each tissue were successfully determined. The 10 FABP isoforms were classified into three categories: (1) isoforms FABP7 and 12 were not markedly expressed in any tissue examined; (2) isoforms showing certain transcript levels in multiple tissues; and (3) isoforms FABP6, 8, and 9, expressed at certain levels in one particular tissue. Based on the expression profiles of the isoforms, individual tissues were also classified into three groups: (1) tissues in which high-level expression of FABP isoforms was not observed, (2) tissues in which multiple FABP isoforms were expressed at certain levels, and (3) tissues in which a single FABP isoform was dominantly expressed at a certain level. These results give a better understanding of the meaning of the presence of multiple FABP isoforms in mammals.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19565192     DOI: 10.1007/s10529-009-0065-7

Source DB:  PubMed          Journal:  Biotechnol Lett        ISSN: 0141-5492            Impact factor:   2.461


  16 in total

1.  Pseudogenes of rat VDAC1: 16 gene segments in the rat genome show structural similarities with the cDNA encoding rat VDAC1, with 8 slightly expressed in certain tissues.

Authors:  Yusuke Ido; Takenori Yamamoto; Tatsuki Yoshitomi; Atsushi Yamamoto; Eriko Obana; Kazuto Ohkura; Yasuo Shinohara
Journal:  Mamm Genome       Date:  2011-11-20       Impact factor: 2.957

2.  Perilipin 5 and liver fatty acid binding protein function to restore quiescence in mouse hepatic stellate cells.

Authors:  Jianguo Lin; Shizhong Zheng; Alan D Attie; Mark P Keller; David A Bernlohr; William S Blaner; Elizabeth P Newberry; Nicholas O Davidson; Anping Chen
Journal:  J Lipid Res       Date:  2018-01-09       Impact factor: 5.922

3.  Overexpression of heart-type fatty acid binding protein enhances fatty acid-induced podocyte injury.

Authors:  Qing Gao; Alhossain Sarkar; Yizhi Chen; Bo Xu; Xiaojuan Zhu; Yang Yuan; Tianjun Guan
Journal:  Exp Ther Med       Date:  2017-12-15       Impact factor: 2.447

4.  Prognostic impact of the serum heart-type fatty acid-binding protein (H-FABP) levels in patients admitted to the non-surgical intensive care unit.

Authors:  Akihiro Shirakabe; Nobuaki Kobayashi; Noritake Hata; Masanori Yamamoto; Takuro Shinada; Kazunori Tomita; Masafumi Tsurumi; Masato Matsushita; Hirotake Okazaki; Yoshiya Yamamoto; Shinya Yokoyama; Kuniya Asai; Wataru Shimizu
Journal:  Clin Res Cardiol       Date:  2014-05-10       Impact factor: 5.460

5.  Fatty acid binding protein deletion suppresses inflammatory pain through endocannabinoid/N-acylethanolamine-dependent mechanisms.

Authors:  Martin Kaczocha; Sherrye T Glaser; Thomas Maher; Brendan Clavin; John Hamilton; Joseph O'Rourke; Mario Rebecchi; Michelino Puopolo; Yuji Owada; Panayotis K Thanos
Journal:  Mol Pain       Date:  2015-08-28       Impact factor: 3.395

Review 6.  From Fertilisation to Implantation in Mammalian Pregnancy-Modulation of Early Human Reproduction by the Endocannabinoid System.

Authors:  Katerina N Bambang; Tulay Karasu; Alpha Gebeh; Anthony H Taylor; Timothy H Marczylo; Patricia Lam; Jonathon M Willets; Justin C Konje
Journal:  Pharmaceuticals (Basel)       Date:  2010-09-02

7.  Urinary Liver-Type Fatty Acid-Binding Protein Level as a Predictive Biomarker of Acute Kidney Injury in Patients with Acute Decompensated Heart Failure.

Authors:  Keiichi Hishikari; Hiroyuki Hikita; Shun Nakamura; Shun Nakagama; Masahumi Mizusawa; Tasuku Yamamoto; Junichi Doi; Yosuke Hayashi; Yuya Utsugi; Makoto Araki; Yuta Sudo; Shigeki Kimura; Atsushi Takahashi; Takashi Ashikaga; Mitsuaki Isobe
Journal:  Cardiorenal Med       Date:  2017-06-21       Impact factor: 2.041

8.  Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia.

Authors:  Martin Kaczocha; Mario J Rebecchi; Brian P Ralph; Yu-Han Gary Teng; William T Berger; William Galbavy; Matthew W Elmes; Sherrye T Glaser; Liqun Wang; Robert C Rizzo; Dale G Deutsch; Iwao Ojima
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

9.  The Concise Guide to PHARMACOLOGY 2013/14: overview.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; John C McGrath; William A Catterall; Michael Spedding; John A Peters; Anthony J Harmar; N Abul-Hasn; C M Anderson; C M H Anderson; M S Araiksinen; M Arita; E Arthofer; E L Barker; C Barratt; N M Barnes; R Bathgate; P M Beart; D Belelli; A J Bennett; N J M Birdsall; D Boison; T I Bonner; L Brailsford; S Bröer; P Brown; G Calo; W G Carter; W A Catterall; S L F Chan; M V Chao; N Chiang; A Christopoulos; J J Chun; J Cidlowski; D E Clapham; S Cockcroft; M A Connor; H M Cox; A Cuthbert; F M Dautzenberg; A P Davenport; P A Dawson; G Dent; J P Dijksterhuis; C T Dollery; A C Dolphin; M Donowitz; M L Dubocovich; L Eiden; K Eidne; B A Evans; D Fabbro; C Fahlke; R Farndale; G A Fitzgerald; T M Fong; C J Fowler; J R Fry; C D Funk; A H Futerman; V Ganapathy; B Gaisnier; M A Gershengorn; A Goldin; I D Goldman; A L Gundlach; B Hagenbuch; T G Hales; J R Hammond; M Hamon; J C Hancox; R L Hauger; D L Hay; A J Hobbs; M D Hollenberg; N D Holliday; D Hoyer; N A Hynes; K-I Inui; S Ishii; K A Jacobson; G E Jarvis; M F Jarvis; R Jensen; C E Jones; R L Jones; K Kaibuchi; Y Kanai; C Kennedy; I D Kerr; A A Khan; M J Klienz; J P Kukkonen; J Y Lapoint; R Leurs; E Lingueglia; J Lippiat; S J Lolait; S C R Lummis; J W Lynch; D MacEwan; J J Maguire; I L Marshall; J M May; C A McArdle; J C McGrath; M C Michel; N S Millar; L J Miller; V Mitolo; P N Monk; P K Moore; A J Moorhouse; B Mouillac; P M Murphy; R R Neubig; J Neumaier; B Niesler; A Obaidat; S Offermanns; E Ohlstein; M A Panaro; S Parsons; R G Pwrtwee; J Petersen; J-P Pin; D R Poyner; S Prigent; E R Prossnitz; N J Pyne; S Pyne; J G Quigley; R Ramachandran; E L Richelson; R E Roberts; R Roskoski; R A Ross; M Roth; G Rudnick; R M Ryan; S I Said; L Schild; G J Sanger; K Scholich; A Schousboe; G Schulte; S Schulz; C N Serhan; P M Sexton; D R Sibley; J M Siegel; G Singh; R Sitsapesan; T G Smart; D M Smith; T Soga; A Stahl; G Stewart; L A Stoddart; R J Summers; B Thorens; D T Thwaites; L Toll; J R Traynor; T B Usdin; R J Vandenberg; C Villalon; M Vore; S A Waldman; D T Ward; G B Willars; S J Wonnacott; E Wright; R D Ye; A Yonezawa; M Zimmermann
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

10.  Induction of body weight loss through RNAi-knockdown of APOBEC1 gene expression in transgenic rabbits.

Authors:  Geneviève Jolivet; Sandrine Braud; Bruno DaSilva; Bruno Passet; Erwana Harscoët; Céline Viglietta; Thomas Gautier; Laurent Lagrost; Nathalie Daniel-Carlier; Louis-Marie Houdebine; Itzik Harosh
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.